WHO WE ARE
An independent health care consulting firm founded by Principals with many years of experience consulting and providing support for life sciences clients including pharmaceutical, biotechnology, device and diagnostic manufacturers, and payers.
Our Principals and Director have extensive experience in health policy working with federal clients including the U.S. Food and Drug Administration, the Department of Health and Human Services Assistant Secretary for Planning and Evaluation (ASPE), and the Centers for Disease Control and Prevention.
Caleb AlexanderMD, MS
CO-FOUNDER & PRINCIPAL
Jonothan TierceCPhil
CO-FOUNDER & PRINCIPAL
William PadulaPhD
PRINCIPAL
Natalie ReidPhD, MPH, MBA
DIRECTOR
CONSULTING TEAM
Francine Chingcuanco, MHS
MANAGER
Francine Chingcuanco, MHS
Francine Chingcuanco’s background is in epidemiology and pharmacology. Prior to joining Monument, she consulted for the Health Outcomes Research Department of Millennium Health wherein she designed and managed clinical research studies aimed at developing real-world evidence to support products in the field of personalized medicine. She holds a Masters in Health Science from Johns Hopkins Bloomberg School of Public Health as well as an Honours Bachelor of Science from the University of Toronto.
Benjamin Cohen, PhD, MPH
MANAGER
Benjamin Cohen, PhD, MPH
Benjamin Cohen specializes in health economics and outcomes research. He is a PhD candidate at the University of Southern California School of Pharmacy where he evaluates the costs and benefits of spending in chronic diseases using administrative claims, microsimulations, and survey data. Prior to starting his doctorate program, he received a Masters in Public Health from Columbia University Mailman School of Public Health. He has previous experience working in the pharmaceutical and biotechnology industry
Elena Fernandez, PharmD, PhD
MANAGER
Elena Fernandez, PharmD, PhD
Elena Fernandez specializes in pharmacoeconomics and health outcomes. She is a PhD candidate in the Department of Pharmacotherapy and Outcomes Sciences at Virginia Commonwealth University, where she designs and conducts research applying econometric models to evaluate opioid utilization in cancer survivors. Prior to her graduate training, she worked as a cancer research training award (CRTA) fellow at the National Cancer Institute. She holds a Doctor of Pharmacy from Virginia Commonwealth University and a Bachelor of Science in biochemistry from the University of Mary Washington.
Omar Mansour, MHS
MANAGER
Omar Mansour, MHS
Omar Mansour specializes in the application of pharmacoepidemiology methods. Prior to joining Monument, he was a scholar at the Johns Hopkins Bloomberg School of Public Health’s Center for Drug Safety and Effectiveness where he designed and conducted comparative effectiveness studies on various topics using electronic medical records, commercial insurance claims, and large national surveys. He holds a Masters in Health Science from Johns Hopkins Bloomberg School of Public Health and a Bachelor of Arts in biology with a minor in statistics from Macalester College.
Katharine Ozenberger, MPH, PhDc
MANAGER
Katharine Ozenberger, MPH, PhDc
Katharine Ozenberger specializes in epidemiology and pharmacoepidemiology. She is a PhD candidate in the Department of Pharmacy Systems, Outcomes, and Policy at the University of Illinois at Chicago where she designs and conducts research using longitudinal data from population-based cohorts, prescription dispensing, and commercial insurance claims. She holds a Masters in Science in epidemiology from the University of Illinois at Chicago’s School of Public Health and a Bachelor of Science in biology from the University of Colorado Denver.
Danyang Wang, MHS
SENIOR ANALYST
Danyang Wang, MHS
Danyang Wang specializes in economic modeling and cost-effectiveness analysis. Before joining Monument Analytics she developed probabilistic Markov models to assess the cost-effectiveness of community health interventions while in training at Johns Hopkins Bloomberg School of Public Health. She holds a Master of Health Science from Johns Hopkins Bloomberg School of Public Health and a Bachelor of Science in Biology with a minor in Economics from Emory University.
Karen Dietz, MHS
CONSULTANT
Karen Dietz,MHS
Karen Dietz, MHS, Consultant, specializes in complex project management, outcomes research, and vaccines. Previously, she worked as a management consultant with enterprise clients across a variety of sectors, including life sciences and pharmaceutical industries. Karen has experience managing multiple outcomes-based research programs and clinical trials at the Johns Hopkins School of Medicine. Karen holds a Master of Health Science from Johns Hopkins Bloomberg School of Public Health, with a Certificate in Vaccine Science and Policy, and a Bachelor of Science from Virginia Tech.
Ellen Hu, MHS
CONSULTANT
Ellen Hu, MHS
Ellen Hu specializes in economic evaluation and has background in healthcare actuarial modeling. Prior to joining Monument, she worked in actuarial consulting where she performed valuations and projections for public and private employer sponsored retiree health plans as well as performed health plan rate settings and design modeling. She holds a Master of Health Science from Johns Hopkins Bloomberg School of Public Health and a Bachelor of Arts in Economics with a minor in Mathematics from DePauw University.
Shreena Malaviya, MHS
CONSULTANT
Shreena Malaviya, MHS
Shreena Malaviya specializes in health economics and modeling. Her background is in pharmacology and management. Previously, she worked as consultant internationally on projects such as building capacity in health economics, and analyzing the effectiveness and efficiency of health systems. She has also worked in reimbursement and risk management for specialty drug products. She holds a Masters in Health from Johns Hopkins Bloomberg school of Public Health and a Bachelor of Science from McGill University.
Divya Mohan, MHS
CONSULTANT
Divya Mohan, MHS
Divya Mohan’s background is in health economics and biomedical engineering. She specializes in patient preferences and cost-effectiveness analysis. Previously she worked at the Economist Intelligence Unit on projects including concept testing, communications strategy, market sizing, as well as customer perception and insight studies for imaging systems, in-vitro diagnostics, surgical devices, and procedures. She holds a Masters in Health Science from Johns Hopkins Bloomberg School of Public Healthand a Bachelor of Engineering from Nanyang Technological University.
Emma Tassie, MS
CONSULTANT
Emma Tassie, MS
Emma Tassie specializes in economic evaluation and patient preferences. She is a PhD candidate in the Health Economics Research Unit (HERU), University of Aberdeen, where she is investigating the use of existing data to incorporate broader measures of benefit in economic evaluation. Prior to her PhD, Emma worked as a researcher at HERU where she conducted economic evaluations alongside randomized controlled trials and developed health economic models to accompany systematic reviews. She has a Masters in Science in Health Economics and a Bachelor of Arts (Economics and Sociology) from University College Cork.
Jeromie Ballreich, PhD, MS
CONSULTANT
Jeromie Ballreich
Jeromie Ballreich is an Assistant Scientist and Director of the Master of Health Sciences in Health Economics program in the Department of Health Policy and Management at Johns Hopkins Bloomberg School of Public Health. He received his Ph.D. in Health Economics from Johns Hopkins Bloomberg School of Public Health with a thesis in “Price Discrimination in the US Cancer Drug Market.” Previously, Dr. Ballreich received a Master in Health Economics also from JHSPH and a Bachelors in Mathematics and Economics from Lafayette College.
Elisabeth H. Hazard, PhD
CONSULTANT
Elisabeth H. Hazard, PhD
Dr. Hazard has over twenty years of experience working as a health care consultant. She was a founding leader of Value Medics Research, Inc. Her specialty is value development and value communications. She was an early pioneer in creating value development plans for medical technologies and facilitated the understanding of how demonstrations of economic value could be used effectively by product development and marketing teams. Dr. Hazard has worked with major pharmaceutical companies in the U.S. and Europe and on dozens of medical technologies
You? Join Us
WORK WITH MA
TOP TALENT?
We always want to meet top talent. If you have rigorous training, great interpersonal skills and a passion for bringing innovative health care solutions to market, contact us. We want to know more about you.
SENIOR SCIENTIFIC ADVISORS
Kim Heithoff, MPH, SCD
SENIOR SCIENTIFIC ADVISOR
Kim Heithoff, MPH, SCD
Dr. Heithoff has over 20 year of experience in the pharmaceutical industry with companies such as Merck, Novartis, and Schering-Plough. He has extensive experience and knowledge in outcomes research and market access. He has worked across multiple therapy areas across the continuum of the product development life cycle. Of particular interest is the integration of health technology assessment requirements into the earliest phases of drug development and leveraging the clinical development program to mitigate risks to pricing and reimbursement. Areas of expertise include identification of value evidence needs and the strategic planning requirements around market access, health policy and strategic value evidence generation, and communication. He received both a Master of Public Health (MPH) and a Doctor of Science (ScD) from the Johns Hopkins University Bloomberg School of Public Health.
Daniel Touchette, PharmD, MA, FCCP
SENIOR SCIENTIFIC ADVISOR
Daniel Touchette, PharmD, MA, FCCP
Daniel Touchette is Professor and Director of Graduate Studies for the Masters in Comparative Effectiveness Research program at the University of Illinois at Chicago’s College of Pharmacy. His primary research interests are evaluating the cost-effectiveness of pharmaceutical agents assessing the effectiveness and cost-effectiveness of clinical pharmacist and other health practitioner services, and developing and assessing methods for improving adherence to medication regimens. Dr. Touchette has obtained grant funding from AHRQ, NIH, and numerous foundations and other sources. Most recently, he has developed decision models for the Institute for Clinical and Economic Review (ICER) and leads UIC’s involvement in ICERs Health Economic Network. He has authored over 70 peer-reviewed manuscripts and reports.
Brett McQueen, PhD
SENIOR SCIENTIFIC ADVISOR
Brett McQueen, PhD
Dr. Brett McQueen is currently a tenure-track Assistant Professor at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences and a member in the Center for Pharmaceutical Outcomes Research (CePOR). His research interests include comparative effectiveness research, cost-effectiveness applications and methods development, value-based outcomes contracting, and patient preferences research. He’s active in health economics-related societies such as the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) through contributions to ISPOR short courses, workshops, issue panels, and research presentations. Dr. McQueen has led or collaborated on modeling submissions for various health technology assessment groups since 2016. He has authored over 50 publications in journals such as PharmacoEconomics, Diabetes Care, and Medical Care.
ADVISORY BOARD MEMBERS
Adrian Levy, PhD
ADVISORY BOARD MEMBER
Adrian Levy, PhD
Adrian R. Levy PhD is Professor in the Department of Epidemiology and Community Health at Dalhousie University. He is author of over 150 peer reviewed publications and is the co-editor of two volumes in the Springer Handbook of Health Services Research entitled “Comparative Effectiveness Research” and “Health Services Evaluation”. His academic interests lie in health services research, health technology assessment, pharmacoepidemiology, pharmacoeconomics, quality of life, and access to care.
Mark Sculpher, PhD
ADVISORY BOARD MEMBER
Mark Sculpher, PhD
Mark Sculpher is Professor of Health Economics at the Centre for Health Economics, University of York, UK where he leads the Centre’s Programme on Economic Evaluation and Health Technology Assessment. He is also Co-Director of the Policy Research Unit in Economic Evaluation of Health and Care Interventions, a programme of research for the UK Department of Health and Social Care funded by the National Institute for Health Research (NIHR).
Mark has worked in the field of economic evaluation and health technology assessment for over 30 years. He has researched in a range of clinical areas including heart disease, cancer, diagnostics, and public health. He has also contributed to research methods in the field, in particular relating to decision analytic modelling and techniques to handle uncertainty, heterogeneity and generalisability. He is also experienced in economic analysis in low income settings and is principle investigator of the Thanzi la Onse (Health for All) programme in Malawi funded by UK Research and Innovation. He has over 270 peer-reviewed publications and is a co-author of two major text books in the area: Methods for the Economic Evaluation of Health Care Programmes (OUP, 2015 with Drummond, Claxton, Torrance and Stoddart) and Decision Modelling for Health Economic Evaluation (OUP, 2006 with Briggs and Claxton).
Mark is an emeritus member of the UK NIHR College of Senior Investigators. Hehas also been a member of the National Institute for Health and Clinical Excellence (NICE) Technology Appraisal Committee and the NICE Public Health Interventions Advisory Committee. He currently sits on NICE’s Diagnostics Advisory Committee. He chaired NICE’s 2004 Task Group on methods guidance for economic evaluation and advised the Methods Working Party for the 2008 update of this guidance. Mark has advised the UK House of Commons Health and Social Care Select Committee, as well as health systems internationally on health technology assessment methods including those in France, Ireland, Japan, Singapore, Germany, Portugal, Taiwan and New Zealand. He has been a member of the Commissioning Board for the UK NHS Health Technology Assessment Programme, the UK NIHR /Medical Research Council’s Methodology Research Panel and the UK Department of Health’s Policy Research Programme’s Commissioning Panel. He served as President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (2011-12).